Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Deloitte
Covington
Moodys
US Army
Merck
Farmers Insurance
Citi
QuintilesIMS
Cerilliant

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,222,219

« Back to Dashboard

Summary for Patent: 8,222,219
Title:Glucopyranoside compound
Abstract: A compound of the formula: ##STR00001## wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is --(CH.sub.2).sub.n-- (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
Inventor(s): Nomura; Sumihiro (Kawaguchi, JP), Kawanishi; Eiji (Kitamoto, JP), Ueta; Kiichiro (Wako, JP)
Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka, JP)
Application Number:13/174,814
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,222,219

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-002 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-001 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-003 Sep 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-001 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-002 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-004 Aug 8, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-002 Mar 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,222,219

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,482,330 Substituted fused heterocyclic C-glycosides ➤ Subscribe
7,816,330 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides ➤ Subscribe
7,084,124 Substituted indazole-O-glucosides ➤ Subscribe
7,511,022 Substituted indole-O-glucosides ➤ Subscribe
7,943,788 Glucopyranoside compound ➤ Subscribe
7,935,674 Indole derivatives ➤ Subscribe
7,816,331 Substituted indazole-O-glucosides ➤ Subscribe
7,820,630 Substituted indole-O-glucosides ➤ Subscribe
8,202,984 Glucopyranoside compound ➤ Subscribe
7,094,763 Substituted fused heterocyclic C-glycosides ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,222,219

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 87991 ➤ Subscribe
Ukraine 86599 ➤ Subscribe
Ukraine 86042 ➤ Subscribe
Ukraine 85569 ➤ Subscribe
Ukraine 83377 ➤ Subscribe
Ukraine 83243 ➤ Subscribe
Taiwan 200526678 ➤ Subscribe
Taiwan 200524951 ➤ Subscribe
Taiwan 200524950 ➤ Subscribe
Taiwan 200521131 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Colorcon
Mallinckrodt
Accenture
Daiichi Sankyo
Covington
Cerilliant
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot